Ocumension Therapeutics
1477.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.08B
Close$
Share Statistics
| Market cap | $4.08 Billion |
|---|---|
| Enterprise Value | $4.11 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.2 |
| Beta | 0.43 |
| Outstanding Shares | 825,119,000 |
Return
| Return on Equity | -10.34% |
|---|---|
| Return on Assets | -9.09% |
| Return on Invested Capital | -10.52% |
Valuation & Multiples
| P/E Ratio | -28.19 |
|---|---|
| PEG | 112.01 |
| Price to Sales | 5.08 |
| Price to Book Ratio | 1.27 |
| Enterprise Value to Revenue | 2.78 |
| Enterprise Value to EBIT | -10.15 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$545.05 M
Average shareholder expectationNext Earnings Call
Expected Date
March 19, 2027
EPS Estimate
$0.05
Average shareholder expectationRevenue Estimate
$751.43 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Ocumension Therapeutics
608 employees
CEO: Ye Liu Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction o...